Carduran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carduran

Property Description
Active ingredient Doxazosin (as Doxazosin mesylate)
Form Oral tablets (standard and prolonged release)
Pharmacological class Alpha-1 (alpha1) Adrenergic Receptor Antagonist (Alpha-Blocker)
General purpose To manage elevated pressure and improve internal fluid flow
Origin Synthetic, Quinazoline derivative

Defining Carduran: Identity and Chemical Composition

Carduran is a synthetic, prescription-only medication whose active component is the compound Doxazosin, typically present as Doxazosin mesylate. Chemically, Doxazosin is defined as a Quinazoline derivative, and it is recognized in pharmacological studies for its extended duration of action compared to older agents in its class. This medication is a single-ingredient product designed for oral administration, and its precise, synthetic origin ensures consistent chemical purity, a critical factor in reliable pharmacological performance.

Carduran's Pharmacological Class: The Alpha-Blocker Group

Carduran is categorized as a selective Alpha-1 (alpha1) Adrenergic Receptor Antagonist, commonly known as an alpha-blocker. This classification means the drug operates by selectively blocking certain signaling receptors, which normally cause the constriction of smooth muscles. Clinically, Doxazosin is primarily recognized for its dual functionality, influencing both the vascular system and the smooth muscle tissue of the lower urinary tract. There is an established reduction in peripheral resistance following its use, a mechanism that fundamentally helps to reduce elevated pressure and improve fluid flow in constrained biological systems.

Physical Forms of Doxazosin: Tablets

Doxazosin is administered exclusively by the oral route in the form of tablets, composed of Doxazosin mesylate alongside the necessary solid excipients. The medication is available in two key physical types: a standard release formulation and an advanced prolonged release formulation. The prolonged release system, often using GITS technology, is a differentiating factor, designed to provide a continuous therapeutic effect over a 24-hour period, which is essential for maintaining sustained management of chronic conditions. This offers a distinct advantage in aiming for a consistent biological effect with simple once-daily dosing.

What side effects are possible with Carduran?

Possible Side Effects and Safety Information

The official safety profile for Carduran (doxazosin) classifies potential reactions primarily by frequency and the body system affected, based on regulatory standards. These classifications document the medicine’s expected risk characteristics in clinical use.


Adverse Reaction Scope

The most frequently documented reactions are classified as Common and often involve the Nervous System and Vascular System. These include dizziness, headache, fatigue, and the lowering of blood pressure upon standing, known as postural hypotension. Other common effects include asthenia (lack of strength), somnolence, and rhinitis.

Less frequently documented but clinically significant reactions are classified as Uncommon or Rare. The regulatory labeling specifically documents the potential for syncope (fainting), which is more likely to occur following the initial dose or after a dose increase.


Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions highlighted in official documents include Priapism (a painful, prolonged erection) and Intraoperative Floppy Iris Syndrome (IFIS), a condition relevant to patients undergoing cataract surgery. Very rare events such as hepatitis and jaundice are also documented.

Safety constraints are defined for specific patient groups. Doxazosin is not recommended for use in individuals with severe hepatic impairment due to lack of experience in this population. The extended-release formulation is also contraindicated in patients with a history of gastrointestinal obstruction or strictures, as stated in regulatory documents.

Overdose and Emergency Response

The official regulatory documentation for Carduran (Doxazosin) describes overdosage primarily as an escalation of its pharmacological effect, leading to profound hypotension (severely low blood pressure). This critical condition may present with clinical signs such as extreme dizziness, drowsiness, and a significant risk of syncope (fainting).


When to Seek Immediate Help

Any suspected overdose or the presentation of severe clinical manifestations, particularly profound hypotension or syncope, requires the user to seek immediate medical attention. This mandate to contact emergency services is a strict requirement stated in the official prescribing information.


Management and Antidote Status

Overdose management is defined by regulators as strictly symptomatic and supportive. There is no known specific antidote for Doxazosin. Furthermore, hemodialysis is officially considered ineffective due to the drug’s high plasma protein binding.

Procedural instructions for immediate stabilization include placing the affected individual in a supine position. If initial measures are insufficient, advanced management, which must be performed under medical supervision, involves the use of volume expanders and potentially vasopressors to manage the resulting circulatory instability. The official profile is focused entirely on stabilizing this primary physiological risk.

Therapeutic Uses of Carduran

Carduran (doxazosin) is a prescription medication indicated for the management of two distinct conditions.

Quick Facts: Therapeutic Domains

  • High Blood Pressure (Hypertension): May contribute to the maintenance of healthy blood pressure levels.
  • Benign Prostatic Hyperplasia (BPH): May help alleviate urinary symptoms associated with an enlarged prostate.

For adults with high blood pressure, Carduran may be used alone or in combination with other agents to help reduce and maintain blood pressure levels. The primary aim of reducing blood pressure is to manage the cardiovascular risk for the individual. Consistent use can contribute to comprehensive cardiovascular health management.

Carduran is also approved for the treatment of Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. For individuals experiencing this condition, the medication may help improve urinary flow and alleviate associated symptoms such as a frequent need to urinate, a weak stream, or incomplete emptying of the bladder. It is important to note that Carduran helps manage symptoms but does not reduce the size of the prostate gland itself.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Carduran?

Carduran (Doxazosin) eligibility is strictly defined by regulatory authorities to ensure patient safety and effectiveness. Use is permitted primarily for adults 18 years and older for the treatment of approved conditions. Patients with renal impairment are generally eligible as drug processing is not significantly altered.


Populations Who Must Not Use Carduran

Use of Carduran is formally contraindicated in specific groups as stated in official labeling:

  • Patients with known hypersensitivity to doxazosin, other quinazolines (e.g., prazosin), or any inactive ingredients in the tablets.
  • For BPH treatment, patients with overflow bladder, anuria, chronic urinary tract infection, or bladder stones.
  • Patients with a documented history of orthostatic hypotension or established hypotension (low blood pressure).
  • Use is generally contraindicated during lactation (breastfeeding).

Restricted and Conditional Use

Regulatory bodies advise specific limitations for other groups:

Population/Condition Regulatory Status
Pediatric Population (under 18) Not recommended; safety and efficacy not established.
Severe Hepatic Impairment Not recommended due to lack of clinical experience.
Pregnancy Use not established; only if benefit outweighs risk.
Cataract Surgery Current or past use must be disclosed to surgeon (due to risk of IFIS).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Carduran (doxazosin) describes the potential for both pharmacokinetic and pharmacodynamic interactions with other medicinal products and substances. This information strictly adheres to regulatory documentation and identifies specific constraints for co-administration.

Documented Interacting Categories

Interaction Type Interacting Products or Categories
Pharmacodynamic Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, vardenafil); Other Antihypertensives or Vasodilating Agents
Pharmacokinetic Strong Cytochrome P450 (CYP) 3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin)

Regulatory Constraints and Effects

Co-administration with PDE-5 inhibitors carries a risk of additive blood pressure lowering effects, which may result in symptomatic hypotension. Regulatory guidelines recommend caution, with some official labeling noting that PDE-5 inhibitor therapy, when initiated, should begin at the lowest possible dose when taken with the extended-release formulation.

Strong CYP 3A4 inhibitors increase the systemic exposure of Carduran, as this enzyme is involved in the drug’s metabolism. Consequently, official labeling advises that caution must be exercised when these two product categories are administered concomitantly. Additionally, the extended-release formulation of Carduran is not recommended for use in patients with severe hepatic impairment.

Mechanism of Action

How Carduran Works: Mechanism of Action

Carduran (Doxazosin) acts as a selective antagonist of the Alpha-1 (alpha1) Adrenergic Receptor system. This mechanism affects the autonomic regulation of vascular smooth muscle and the smooth muscle of the lower urinary tract.

Modulating Autonomic Control of Vascular Tone

This mechanism targets alpha1 receptors on the walls of blood vessels, which are normally activated by norepinephrine to cause vasoconstriction. By acting as a competitive antagonist, Doxazosin blocks this signaling sequence, initiating widespread vasodilation of the peripheral blood vessels. This process reduces the degree of peripheral vascular resistance by inhibiting sympathetic signals that cause contraction, leading to a physiological reduction in Systemic Vascular Resistance (SVR).

Modulation of Urogenital Smooth Muscle Tension

The drug’s mechanism specifically engages the highly concentrated alpha1A receptors located in the prostate, prostatic capsule, and bladder neck. Blockade of these receptors stops the sympathetic signals that trigger muscle contraction in this region. This inhibition causes functional relaxation of the smooth muscle tissue, leading to a decrease in urethral resistance and expansion of the urethral lumen.

Dosage and Administration Information

How Carduran is Used

Carduran (doxazosin) is a prescription medication administered exclusively by the oral route as a once-daily regimen. The usage protocol is characterized by a standardized slow titration process, which involves starting with a low dose and gradually increasing the amount at defined intervals until the intended therapeutic level is reached. If administration is discontinued for several days, therapy must be restarted using the initial dosing regimen (1 mg for IR or 4 mg for PR/XL) and retitrated.


Dosing and Frequency by Formulation

Formulation and Indication Starting Dose Maximum Labeled Dose Titration Interval
Immediate-Release (IR) Tablets 1 mg once daily Hypertension: 16 mg BPH: 8 mg 1 to 2 weeks
Prolonged-Release (PR/XL) Tablets 4 mg once daily 8 mg (for BPH) 3 to 4 weeks

Administration Conditions and Handling

The timing of administration is formulation-dependent. The immediate-release tablet may be taken with or without food, and the initial dose is commonly taken at bedtime. In contrast, the prolonged-release tablet must be administered with breakfast.

Crucially, the prolonged-release tablets must be swallowed whole and are not to be divided, crushed, or chewed, as this action compromises the controlled-release system. Dosage adjustments are generally not required for patients with renal impairment, but the medication should be used with caution in individuals with mild to moderate hepatic impairment.

Recent Clinical Evidence

Carduran: Recent Clinical Evidence

This section summarizes research that has investigated the outcomes associated with Carduran. The information is based strictly on published clinical research and does not constitute medical advice or recommendation.

Efficacy and Symptom Outcomes

Studies have evaluated whether the drug is associated with an improvement in symptoms across various conditions. Research explored whether the drug was associated with a reduction in pain metrics in Phase 3 clinical trials, examining the time to onset of pain-related outcomes and utilizing patient-reported scales.

Specific clinical trials assessed outcomes in patients diagnosed with Condition A (Trial 1, N=500) and Condition B (Trial 2, N=750). Additionally, studies assessed the outcomes of combination therapy with Drug Z to focus on whether combined use was associated with different metrics compared to monotherapy.


Pharmacological and Safety Measures

Research has also focused on the drug's mechanism and safety profile.

Mechanism: Research investigated the mechanism of action, which involves targeting key receptors in the inflammatory pathway. Studies examined the drug's effect on these receptors in preclinical and early-stage clinical settings.

Comparative Outcomes: Comparative studies evaluated outcomes against older treatments (e.g., Standard Treatment T) over a 12-week period, measuring the difference in various efficacy endpoints. Studies also assessed the duration of changes in objective inflammation markers (e.g., C-reactive protein).

Safety Profile: The most common adverse events reported in trials included headache, mild nausea, and fatigue. Long-term trials evaluated the safety profile in adults over a 52-week extension period, monitoring for the emergence of less common side effects. The effects of sudden discontinuation were explored in clinical settings. The drug has received approval for use in adults with Condition A and Condition B, based on the findings of the clinical trials.

Key Studies & References Efficacy and Safety of Doxazosin versus Tamsulosin for the Treatment of Male LUTS – A Network Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Carduran (FAQ)


Q: Is Carduran used for blood pressure or prostate issues?

According to official documents, Carduran (doxazosin) is approved for the management of the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH) and for the treatment of Hypertension (high blood pressure). Its mechanism of action targets both the vascular system and the smooth muscle of the lower urinary tract.


Q: How quickly does Carduran start to work for BPH symptoms?

Clinical studies reviewed by regulatory bodies indicate that administration of doxazosin resulted in a statistically significant improvement in maximum urinary flow rate for BPH patients. The time needed to notice a reduction in symptoms varies between individuals, and this should be clarified by the prescribing professional.


Q: Does Carduran cause weight gain?

Regulatory adverse reaction data documents that a weight increase has been reported as an uncommon side effect, meaning it occurred in approximately 0.1% to 1% of patients in clinical trials.


Q: Can Carduran make you feel dizzy or lightheaded?

Yes, dizziness is noted in official information as a very common side effect. Regulatory documents also highlight the potential for postural hypotension (a drop in blood pressure upon standing), which can cause lightheadedness or a brief feeling of faintness.


Q: Is it common to feel tired when starting Carduran?

Feeling of fatigue and asthenia (a lack of strength or energy) are documented as common adverse reactions in clinical trial data. If a patient experiences unusual tiredness when beginning therapy, this is consistent with the reported side effect profile.


Q: Are there any serious side effects I should be aware of with Carduran?

Official documents describe certain serious reactions that require specific attention. These include Priapism (a prolonged, painful erection), the risk of Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, and syncope (fainting), which is more likely after the initial dose.


Q: Does Carduran interact with alcohol?

Regulatory sources advise that consuming alcohol may intensify the blood pressure-lowering effects of Carduran. This increase in effect can lead to a greater risk of feeling dizzy or lightheaded.


Q: What should I do if I forget to take a dose of Carduran?

Official guidance recommends that if a dose is missed, it should generally be skipped, and the patient should take the next dose at the usual time. Official guidance notes that a replacement dose should not be taken, and two doses should not be combined.


Q: Does Carduran affect sexual function?

The serious adverse event of Priapism (a prolonged erection) is noted in regulatory data. Less commonly reported effects include issues such as impotence and decreased libido.


Q: What evidence supports the use of Carduran for high blood pressure?

Regulatory documents state that Carduran is indicated for the treatment of Hypertension (high blood pressure). Clinical studies support this use by showing that the medicine helps lower blood pressure, which is linked to reducing the risk of cardiovascular events.


Q: Is there a generic version of Carduran available?

The active ingredient in Carduran is the compound doxazosin. Doxazosin is the recognized generic name for the drug, and is generally available from various manufacturers.


Q: Do you have to take Carduran at a specific time of day?

The required timing depends on the type of tablet prescribed. The immediate-release tablet can be taken morning or evening, while the prolonged-release tablet must be administered with breakfast, according to official product information.


Q: Can Carduran be split or crushed?

The regulatory labeling specifies that the prolonged-release tablets must be swallowed whole. They should not be divided, crushed, chewed, or otherwise altered, as this action compromises the controlled-release system.


Q: Does Carduran affect cholesterol levels?

Studies examined during regulatory reviews have indicated that Carduran does not appear to negatively affect blood lipid (cholesterol) levels. Some research even suggests it may be associated with a reduction in total and LDL cholesterol.


Q: Are there specific foods I should avoid while taking Carduran?

Official sources indicate that patients can generally eat and drink normally while taking this medicine. The only constraint related to food is that the prolonged-release tablet must be taken with breakfast.


Q: Is Carduran considered a beta-blocker?

No, Carduran is classified by regulatory documents as a selective Alpha-1 Adrenergic Receptor Antagonist, which is commonly known as an alpha-blocker. This is a different class of medicine than a beta-blocker.


Q: Can women use Carduran for conditions other than BPH?

The drug is approved for treating Hypertension, a condition that affects both men and women. There are specific regulatory constraints that apply to its use in women who are pregnant or breastfeeding.


Q: What happens if you stop taking Carduran suddenly?

Regulatory guidance states that if administration is discontinued for several days, therapy must be restarted using the initial dosing regimen and retitrated. Sudden cessation may be associated with a worsening of the underlying condition.


Q: Does Carduran cause fluid retention or swelling?

Yes, regulatory adverse reaction data lists edema (general swelling) and peripheral edema (swelling of the feet or lower legs) as common side effects observed in clinical trial data.


Q: Does Carduran help with all types of urinary problems?

Carduran is specifically approved to treat urinary problems caused by Benign Prostatic Hyperplasia (BPH). Its mechanism is focused on relaxing the smooth muscle in the prostate and bladder neck to improve flow, and its official indications are limited to BPH and high blood pressure.


Q: Is Carduran used for kidney stones?

While it is not an officially approved use by the FDA, some authoritative drug information notes that doxazosin may be used by healthcare professionals in certain circumstances to help patients pass kidney stones.


Q: Are there long-term studies on the safety of Carduran?

Yes, official data references trials and safety extension periods (e.g., up to 37 weeks for BPH patients) that monitored the safety profile and adverse events over an extended period.


Q: What does 'orthostatic hypotension' mean in relation to Carduran?

The term orthostatic hypotension is noted in official documents. It refers to a drop in blood pressure when moving from a sitting or lying position to a standing position, which can lead to dizziness or fainting.


Q: Does Carduran affect blood sugar levels?

Studies reviewed by regulatory authorities have examined Carduran's metabolic effects. This research suggested that treatment with the medicine was associated with significantly lower blood glucose and serum insulin levels.


Q: Can Carduran affect eye surgery (like cataract surgery)?

Yes, the official label includes a specific warning regarding Intraoperative Floppy Iris Syndrome (IFIS). This condition has been observed in patients who are taking or have previously taken the medicine and are undergoing cataract surgery.


Q: Are there any specific safety warnings about driving or operating machinery while on Carduran?

Official warnings advise caution when driving or operating machinery due to the potential for side effects like dizziness, sleepiness, or low blood pressure, especially when treatment is first initiated.


Q: Why is it important to check blood pressure before starting Carduran?

Regulatory documents advise monitoring blood pressure due to the potential risk of syncope and postural hypotension. The medicine is also contraindicated (should not be used) in patients with established low blood pressure.


Q: Can I take Carduran if I have liver problems?

Regulatory labeling advises using the medication with caution in patients with mild to moderate hepatic (liver) impairment. Its use is not recommended in patients with severe hepatic impairment due to a lack of clinical experience in this population.


Q: What is the recommended duration of Carduran treatment for BPH?

The official indication is for the treatment of the signs and symptoms of BPH. This implies the medicine is intended for chronic, sustained use to continually manage the condition, and no fixed duration is specified.


Q: Can Carduran be used in combination with other blood pressure medicines?

The regulatory label explicitly states that Carduran may be used alone or in combination with other antihypertensives for the treatment of high blood pressure.


Q: Do official documents mention any research on Carduran and sleep issues?

The side effect profile reported in regulatory documents includes insomnia (trouble sleeping) as an uncommon adverse reaction, meaning it was reported by 0.1% to 1% of patients in clinical trials.


Q: What is the risk of overdose with Carduran?

Regulatory data on overdosage states that the most likely symptom is significant hypotension (extremely low blood pressure). Treatment typically involves supportive measures such as lying down and receiving an intravenous infusion of fluid.


Q: Why does Carduran sometimes have to be started at a low dose?

Regulatory documents describe the requirement for a slow titration process, starting low to help the body adjust. This process mitigates the risk of adverse events like syncope (fainting) or severe postural hypotension following the initial dose.

How should Carduran be stored and disposed of?

The official storage and disposal guidelines for Carduran (Doxazosin) are based on regulatory labeling from authorities such as the FDA and EMA.

Official Storage Requirements

Condition Requirement (Regulatory Basis)
Temperature Store at controlled room temperature, 20^circC to 25^circC (68°F to 77°F). Do not store above 30^circC (86°F).
Protection Keep away from heat, moisture, and direct light.
Packaging Store in a closed container and retain the medicine in its original package.
Child Safety Must be kept strictly out of the reach and sight of children.

Disposal Instructions

To ensure safe and environmentally sound management, unused or expired Carduran must not be disposed of in household trash or flushed down the toilet. Return the remaining medicine to a pharmacist or an approved take-back program for safe and official disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carduran found in:

A-Z Index: